Coramitug is a humanized monoclonal antibody under investigation for transthyretin amyloidosis with cardiomyopathy (ATTR-CM). It targets misfolded transthyretin and is designed to promote amyloid clearance. Phase 2 data reported biomarker improvement at the higher dose but no statistically significant six-minute walk benefit within 52 weeks.
Prothena reported Q4 and full year 2025 financial results with $308.4 million in cash as partners Roche and Novo Nordisk initiated Phase 3 trials for prasinezumab and coramitug, both expected to complete in 2029.
Prothena reported Q4 2025 adjusted loss of 45 cents per share, meeting estimates, while ending the year with $308.4 million in cash. Roche and Novo Nordisk advanced partnered programs prasinezumab and coramitug into Phase III trials.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07448623 |
A Research Study to Look at the Distribution and Effects of Coramitug on Amyloid Deposits in Heart Tissue Using PET/CT Imaging in People With ATTR Amyloidosis. |
RECRUITING | PHASE1 |
